Sign in
WithdrawnNo phase

Vaping High vs. Low Nicotine E-Liquid

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the 2 sites
Trial code
Status
Withdrawn
Started
1 Jun 2023
Ended
31 Dec 2023
Type of study
Interventional, 2 groups
Treatments tested
  • Low Nicotine E-Liquid
  • Medium or High Nicotine E-Liquid
Record updated
22 August 2023
Why it stopped
Please see NCT04053868 for the current version of this study

Who can take part

Age
21 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 51 criteriaShow less

Who can take part

  • Healthy on the basis of medical history and limited physical examination, as described below:
  • Heart rate < 105 beats per minute (BPM)*
  • Systolic Blood Pressure < 160 and > 90*
  • Diastolic Blood Pressure < 100 and > 50*; *Considered out of range if both machine and manual readings are above/below these thresholds
  • Age: >= 21 years
  • Age: <= 70 years
  • Current regular user of open tank electronic cigarette (EC) (at least 20 times in the past 30 days) with e-liquid nicotine of 3-6 mg/mL
  • Non-smoker or non-daily cigarette smokers agreeing to abstain from cigarettes for the duration of the study
  • Saliva cotinine >50 ng/mL and/or NicAlert=6
  • Carbon monoxide >= 5 ppm or per discretion of Principal Investigator

Who cannot take part

  • Drug/Alcohol Dependence
  • Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
  • Positive toxicology test for illicit drugs at the screening visit (THC \& prescribed medications okay)
  • Opioid replacement therapy (including methadone, buprenorphine, or other)
  • Medications
  • Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs)
  • Concurrent use of nicotine-containing medications
  • Concurrent participation in another clinical trial
  • Concurrent regular use of marijuana (occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study)
  • Heart disease
  • Seizures
  • Cancer
  • Thyroid disease (okay if controlled with medication)
  • Diabetes
  • Hepatitis B or C or Liver disease
  • Kidney disease or urinary retention
  • History of stroke
  • An ulcer in the past year
  • Active use of an inhaler for Asthma or Chronic obstructive pulmonary disease (COPD)
  • Psychiatric conditions
  • Current or past schizophrenia, and/or current or past bipolar disorder
  • Major personality disorder
  • Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the PI and considered for inclusion
  • History of psychiatric hospitalizations is not exclusionary, but study participation will be determined as per PI's approval
  • Psychiatric medications
  • Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and serotonin-norepinephrine reuptake Inhibitors (SNRIs) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate
  • Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers)
  • Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment
  • Other/Misc. Chronic Health Conditions
  • Other "life threatening illnesses" as per PI's discretion
  • Medical
  • Glaucoma
  • Major depression, current or within the past year
  • Oral thrush
  • Fainting (within the last 30 days)
  • Pregnancy
  • Pregnancy (self-reported and urine pregnancy test)
  • Breastfeeding (determined by self-report)
  • Inability to read and write in English
  • Planning to quit vaping within the next 60 days
  • Use of other tobacco products, smokeless tobacco, pipes, cigars/cigarillos, blunts/spliffs (no more than 10 times in the past month and must agree to abstain from their use during the period of the study)

Where in United States

  • University of California San FranciscoSan Francisco, United States
  • Zuckerberg San Francisco General HospitalSan Francisco, United States

About the trial

What the trial wants to find out

This study will examine the effects of electronic cigarette e-liquid nicotine content in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=36). The specific aim is to determine the impact of nicotine content of e-liquid on nicotine pharmacology, systemic exposure to toxic volatile organic compounds, and short-term cardiovascular effects.

The 2 groups in the trial

  • Low NicotineOther group

    Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.

    Treatment: Low Nicotine E-Liquid

  • Medium or High NicotineOther group

    The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.

    Treatment: Medium or High Nicotine E-Liquid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
22 August 2023